Replimune (NASDAQ: REPL) CMO receives stock options and RSUs grant
Rhea-AI Filing Summary
Replimune Group, Inc. reported that Chief Medical Officer Konstantinos Xynos received new equity awards as part of his compensation. He was granted an employee stock option for 75,000 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. Twenty‑five percent of these option shares will vest on April 1, 2027, with the remainder vesting in 36 roughly equal monthly installments.
He also acquired 50,000 shares of common stock through restricted stock units (RSUs). Each RSU represents one share of common stock, with 25% vesting on May 15, 2027 and the rest vesting in three approximately equal annual installments until May 15, 2030, subject to continued service. Following these grants, he directly owns 249,685 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 50,000 shares
Net Buy
2 txns
Insider
Xynos Konstantinos
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 75,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 50,000 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 75,000 shares (Direct);
Common Stock — 249,685 shares (Direct)
Footnotes (2)
- F1. Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer.
- F2. 25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.
Key Figures
Stock options granted: 75,000 shares
Option exercise price: $7.61 per share
Option expiration: April 1, 2036
+3 more
6 metrics
Stock options granted
75,000 shares
Employee stock option grant on April 1, 2026
Option exercise price
$7.61 per share
Exercise price for 75,000-share option grant
Option expiration
April 1, 2036
Expiration date of employee stock option
RSUs granted
50,000 shares
Common stock issuable upon RSU settlement
Initial RSU vesting
25% on May 15, 2027
First vesting date for RSU grant
Common shares after grant
249,685 shares
Total common stock directly owned after transactions
Key Terms
restricted stock units ("RSUs"), Employee Stock Option (right to buy), vest, exercise price
4 terms
restricted stock units ("RSUs") financial
"Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Employee Stock Option (right to buy) financial
"security_title: "Employee Stock Option (right to buy)""
vest financial
"25% of the RSUs will vest on May 15, 2027 and the remainder will vest"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price: "7.6100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Replimune (REPL) disclose about Konstantinos Xynos in this Form 4?
Replimune disclosed that Chief Medical Officer Konstantinos Xynos received new equity awards, including stock options and restricted stock units. These awards increase his long-term equity stake and tie part of his compensation to Replimune’s share performance and his continued service with the company over several years.
How many stock options did Replimune’s CMO receive and at what exercise price?
The CMO received an employee stock option covering 75,000 shares of Replimune common stock at an exercise price of $7.61 per share. This option expires on April 1, 2036 and vests over time, beginning with a 25% vest on April 1, 2027, then monthly thereafter.
What are the details of the RSU grant to Replimune CMO Konstantinos Xynos?
He was granted 50,000 restricted stock units, each representing one share of Replimune common stock. Twenty-five percent of these RSUs vest on May 15, 2027, with the remaining units vesting in three approximately equal annual installments through May 15, 2030, contingent on continued service.
When do the newly granted Replimune stock options and RSUs start vesting?
The stock options begin vesting on April 1, 2027, when 25% of the underlying shares vest, with the remainder vesting monthly thereafter. The RSUs start vesting on May 15, 2027, when 25% vest, followed by three annual installments through May 15, 2030.